Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
83
datasets available to search
ShareScore release 0.9.0
Dataset results
83 results for “Transthyretin amyloidosis”
Assessment of the association of new biomarkers (GDF15, ST2, galectin-3, TIMP-1, MMP-9, NfL) and plasma prothrombotic potential in the course of cardiac transthyretin amyloidosis.
<p><span>The development of cardiac amyloidosis (ATTR) is caused by the deposition of misfolded, insoluble proteins in the extracellular matrix of tissues. An important element of the clinical presentation of the disease is the increased risk of thromboembolic complications. Currently, there is limited published data on the potential role of new heart failure biomarkers in the assessment of ATTR cardiomyopathy, particularly in the assessment of asymptomatic carriers of pathogenic transthyretin (TTR) variants.</span></p> <p><span>Purpose of the study: To assess the diagnostic value of biomarkers related to heart failure (growth differentiation factor-15 (GDF15), soluble suppression of tumorigenicity-2 (ST2), galectin-3), amyloidosis ( retinol binding protein 4 (RBP4, transthyretin) , tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-9 (MMP-9, matrix metalloproteinase-9), neurofilament light chain (NfL)) and the generation potential thrombin as a marker of the prothrombotic state in the course of ATTR.</span></p> <p><span>Methods: This prospective, single-center study included consecutive patients diagnosed with ATTR, asymptomatic carriers of pathogenic TTR variants, and a matched control group of healthy volunteers. The values of these biomarkers were evaluated using the ELISA method from peripheral blood (enzyme-linked immunosorbent assay) GDF15, ST2, RBP4 (TTR), TIMP-1, MMP-9, galectin-3, NfL. Additionally, the prothrombotic potential of plasma was tested using the calibrated automatic thrombogram (CAT) method. Results are presented in Table 1. </span><span>The demographic and clinical characteristics of the study population are presented in Table 2 and Table 3.</span></p> <p><span>Conclusions: The project provides information on the value of novel biomarkers in the assessment of ATTR cardiomyopathy, especially in the assessment of asymptomatic carriers of pathogenic TTR variants. Moreover, it evaluated prothrombotic state in the course of ATTR.</span></p>
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
ClinicalTrials.gov study NCT03862807. IPD Sharing: YES. Countries: 7. Publications: 3.
The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
ClinicalTrials.gov study NCT01961921. IPD Sharing: YES. Countries: 7. Publications: 1.
A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
ClinicalTrials.gov study NCT05139680. IPD Sharing: NO. Countries: 1. Publications: 1.
Transthyretin Amyloidosis Outcome Survey (THAOS)
ClinicalTrials.gov study NCT00628745. IPD Sharing: NO. Countries: 25. Publications: 26.
Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis
ClinicalTrials.gov study NCT01617967. IPD Sharing: YES. Countries: 7. Publications: 1.
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
ClinicalTrials.gov study NCT01960348. IPD Sharing: YES. Countries: 21. Publications: 7.
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
ClinicalTrials.gov study NCT02510261. IPD Sharing: NO. Countries: 21. Publications: 3.
The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
ClinicalTrials.gov study NCT00630864. IPD Sharing: Not stated. Countries: 4. Publications: 4.
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
ClinicalTrials.gov study NCT03759379. IPD Sharing: YES. Countries: 22. Publications: 3.
HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
ClinicalTrials.gov study NCT04153149. IPD Sharing: YES. Countries: 32. Publications: 7.
Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
ClinicalTrials.gov study NCT03842163. IPD Sharing: NO. Countries: 10. Publications: 1.
APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
ClinicalTrials.gov study NCT03997383. IPD Sharing: YES. Countries: 22. Publications: 2.
Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis
ClinicalTrials.gov study NCT00925002. IPD Sharing: YES. Countries: 8. Publications: 5.
Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
ClinicalTrials.gov study NCT04387344. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Validation of a Questionnaire for Quality of Life Assessment in Patients With Transthyretin Amyloidosis.
ClinicalTrials.gov study NCT07080268. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis
ClinicalTrials.gov study NCT01148953. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
ClinicalTrials.gov study NCT01604122. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis
ClinicalTrials.gov study NCT01171859. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Mitochondrial Function in Transthyretin Amyloidosis
ClinicalTrials.gov study NCT03328338. IPD Sharing: YES. Countries: 1. Publications: 6.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.